Changes to the Federal Government’s Insulin Pump Program
The Australian Government’s Insulin Pump Program (IPP), administered by JDRF Australia, provides insulin pumps to young Australians up to the age of 21, living with type 1 diabetes (T1D), who meet certain financial and clinical eligibility requirements. The program supplies fully subsidised insulin pumps to people who would otherwise be unable to access insulin pump therapy.
Earlier this year, the Department of Health and Aged Care undertook an open tender process to establish new insulin pump supply arrangements, following the expiry of the previous supply arrangements.
In October 2023, the Department announced the mylife YpsoPump would be the sole pump available through the IPP.
The Department has advised that while the evaluation panel recognised the value of having a choice of products, ultimately a single supplier was chosen on the basis that this would result in additional people being able to benefit from the program. This was considered particularly important as the program provides insulin pumps to people who would otherwise have no opportunity to access insulin pump therapy.
JDRF provided input about the importance of choice when it comes to diabetes management technology, however, we had no direct involvement in the conduct of the tender process, or the decisions made as a result.
The recently launched mylife YpsoPump, which can be combined with the mylife CamAPS FX mobile application and the Dexcom G6 continuous glucose monitoring (CGM) for an automated insulin delivery system, is now available through the IPP.
The YpsoPump is compatible with the same Android devices that are compatible with the Dexcom G6 CGM. Refer to the list of suitable Android devices here.
JDRF Australia is currently working with Yposmed to distribute pumps as quickly as possible and are currently processing applications and ordering pumps.
We are aware that there may be many questions about the updated program. You can read more about the changes on our IPP FAQs page.
We will keep the community updated as we work through these new arrangements.
If you would like to learn more about the pump, contact Ypsomed on 1800 447 042 or email firstname.lastname@example.org.
If you have a query about an application or any aspect of the IPP, email JDRF at email@example.com.
New support for Australia’s best and brightest early career researchers
JDRF is delighted to announce that three Australian Early to Mid-Career Researchers (EMCRs) are being supported with over $2.2 million to continue their groundbreaking type 1 diabetes (T1D) research. JDRF is committed to nurturing the growth and impact of leading independent researchers who are instrumental in translating scientific discoveries to clinical applications. Dr Aveni Haynes […]
JDRF supports a medical corridor in the Middle East
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organisation, joins healthcare and humanitarian non-profits throughout the world in calling for a medical corridor to allow immediate access to lifesaving supplies and medicines, like insulin, needed by all people living with T1D in the Middle East conflict zone. At all times, including times […]
$3 million invested to understand and prevent the development of T1D
JDRF Australia and The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley) have committed $3 million for research projects aimed at understanding how type 1 diabetes (T1D) develops, with the ultimate goal of preventing it. This is in collaboration with the Environmental Determinants of Islet Autoimmunity (ENDIA) Study. ENDIA is the world’s first T1D observational […]
Advocacy Spotlight: Meet Joanne & Dougal
Dougal has been living with type 1 diabetes (T1D) since the age of 4, a journey that began when he complained of sore legs. Despite the absence of any family history of T1D, Joanne (Jo), a health professional and parent, quickly recognised the signs, drawing on her expertise and a colleague’s experience as a T1D […]